NEW YORK (GenomeWeb) – Exact Sciences today announced zero revenues for the third quarter as it begins commercialization of its Cologuard screening test for colorectal cancer.

Revenues for the three months ended Sept. 30 were down from $1.0 million a year ago and short of the consensus Wall Street estimate of $170,000. Its revenues in the year-ago period comprised non-cash amortization of upfront license fee payments from Genzyme that ended in January 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.